1. Introduction {#s0005}
===============

Diabetes mellitus is on the rise worldwide, and is associated with improvement in socioeconomic conditions, increasing wealth, higher caloric and fat intake and lower physical activity ([@bb0100], [@bb0070]). Accumulating evidence has also suggested the association of environmental factors such as toxins and viruses with diabetes ([@bb0060]). However, the role of these environmental factors in the development of diabetes is not yet fully understood.

Virus infection has long been considered to be a possible cause of type 1 diabetes (T1D), as suggested by many clinical and experimental observations ([@bb0145], [@bb0010]). It was reported that several viruses including coxsackie B virus, cytomegalovirus, varicella-zoster virus, and rubella virus, were found in the pancreatic islets in patients with severe fatal viral infections ([@bb0055]), suggesting that systemic severe viral infections could lead to the pancreatic β-cell damage. Virus-induced diabetes is a more complex disease than previously thought, and is ascribed to diverse mechanisms that may lead to damage of the pancreatic β-cells ([@bb0010]). These mechanisms include direct virolysis, local inflammatory response, and triggering of autoimmunity against β-cells ([@bb0010]). However, the precise mechanisms of pancreatic β-cell damage caused by viral infections remain to be determined, and host factors that control virus-induced diabetes have not been elucidated.

Accumulating evidence strongly suggests the contribution of enteroviruses, which belong to the picornavirus group, to the elevated risk of diabetes ([@bb0140], [@bb0090], [@bb0135]). Since resistance to picornavirus infection has been shown to be dependent on innate immunity ([@bb0040], [@bb0130]), the molecules regulating innate immune responses are candidates for determining susceptibility to virus-induced diabetes ([@bb0065], [@bb0080]). These include interferon itself, interferon production and interferon receptor-mediated signaling pathway-associated molecules including pattern recognition receptors (PRR) directed against pathogen-associated molecular patterns (PAMPs) such as toll-like receptors (TLR) and intracellular helicases such as retinoic acid-inducible gene I (*RIG-I)* and interferon induced with the helicase C domain I (*IFIH1*) or melanocyte differentiation antigen (*MDA*)-*5* (*MDA-5/IFIH1*) ([@bb0130]). Interferon-regulatory factors and interferon receptor-associated downstream molecules including *JAK1*, *TYK2*, *STAT1* and *STAT2* are also important with respect to serving as resistance against viral infections ([@bb0080]) (Supplementary Fig. 1). However, the exact host factors that confer susceptibility to virus-induced diabetes remain uncertain.

Since innate immunity plays a significant role in the protection against experimental encephalomyocarditis (EMC) virus (a picornavirus)-induced diabetes ([@bb0065]), it is suggested that intact operation of the interferon signaling pathway may be important for resistance against virus-induced diabetes. It should be noted that this experimental virus-induced diabetes in mice is an excellent model as rapid onset T1D including fulminant type, but not autoimmune diabetes ([@bb0045], [@bb0080]). A separate study from our group presented experimental evidence that the *Tyk2* gene, an interferon receptor signaling pathway molecule, was responsible for encephalomyocarditis (EMC) virus-induced diabetes susceptibility in mice ([@bb0050]). Highly virus-induced diabetes-susceptible strains such as SJL and SWR mice possessing a mutated *Tyk2* gene, which is associated with reduced expression of *Tyk2* gene in pancreatic β-cells, were prone to the development of diabetes caused by the diabetogenic strain of EMC-D virus ([@bb0050]). Interestingly, a human genome-wide study suggested the T1D susceptibility region to be chromosome 19p13 ([@bb0075]), where the *TYK2* gene was located (19p13.2) ([@bb0030]). However, the exact responsible gene has not yet been identified.

These observations suggest that the human *TYK2* gene may be associated with the risk for T1D and also confer a possible link with virus-induced diabetes susceptibility in humans. We thus examined the association of *TYK2* gene polymorphisms with T1D and type 2 diabetes (T2D), focusing on association with flu-like syndrome at diabetes onset.

2. Methods {#s0010}
==========

2.1. Subjects {#s0025}
-------------

We studied 947 Japanese patients and controls. Those include 302 patients with T1D, 314 patients with T2D and 331 healthy controls. Among the 302 patients with T1D, 73 patients were associated with flu-like syndrome at the onset. Clinical profiles of the Japanese patients with T1D or T2D, and the healthy controls are presented in [Table 1](#t0005){ref-type="table"}.

Patients were designated as T1D if fasting C-peptide was \< 0.5 ng/ml and they were in an insulin-dependent condition (IDDM), or as T2D if fasting blood glucose levels were higher than 126 mg/dl and HbA1c levels exceeded 6.5% with non-insulin-dependent status (NIDDM). Patients with T1D were also grouped according to their age at onset, as 0 to 19 (0--19), 20 to 39 (20--39), 40 to 59 (50--59), and 60 to 79 (60--79) years old. The study was conducted according to the guidelines for human study and was approved by the ethical committee of the Kyushu University, Graduate School of Medical Sciences (No. 433-00). Written informed consent was obtained from all subjects including T1D, T2D and healthy controls involved in this study.

2.2. Genotyping of *TYK2* Gene {#s0030}
------------------------------

Genotyping had been performed to detect 25 exons and the putative promoter region, 1.3 kb upstream of start codon, of the *TYK2* gene. *TYK2* sequence reference was NCBI Reference Sequence: [NG_007872.1](ncbi-n:NG_007872.1){#ir0010}. PCR amplification of the target genes, followed by the direct sequencing of the amplified gene, was conducted. A list of primers used to detect the polymorphisms of the *TYK2* gene is presented in Supplementary Table 1.

2.3. *TYK2* Promoter Variant Gene Analysis {#s0035}
------------------------------------------

To identify the *TYK2* promoter variant, we used PCR analysis followed by direct sequencing to identify − 930G \> A and − 929 T \> A at the promoter region, using the following primer sets: F:5′-GAA TCG CTT GAA TCC GGG AG-3′, and R:5′-ACC CTT CTT CTG TGC CAC AC-3′. Thus, we present *TYK2* promoter genotypes of wild type and variant type as GT and AA, respectively.

2.4. Statistical Analysis {#s0040}
-------------------------

The genotype distribution between the cases and controls was statistically assessed by *χ*^2^ test. Odds ratio (OR) and 95% confidence interval (CI) were estimated by Woolf\'s method. Statistical analysis was done using Stata version 10 (Stata Corporation, College Station, Texas).

3. Results {#s0015}
==========

3.1. Polymorphisms of Human *TYK2* Gene {#s0045}
---------------------------------------

We first screened human *TYK2* gene polymorphisms in 22 patients with T1D associated with flu-like syndrome, suggestive of possible viral infection, by PCR amplification followed by direct sequencing. We found seven polymorphisms: − 930G \> A, − 929T \> A and − 104A \> C at the promoter region from transcription start point at exon 1; 1A \> G, 62G \> A and 63G \> A at exon 1, which is an untranslated region; and 15597G/T at exon 8 with an amino acid substitution from valine to phenylalanine (V326F) ([Fig. 1](#f0005){ref-type="fig"}).

Among them, 1A \> G (rs17000728), 62G \> A (rs17000728) and 63G \> A (rs2304258) at exon 1, and 15597G/T (V326F) at exon 8 (rs2304256) have been already identified by the 1000 Genomes Project that included the Japanese population ([@bb0150], [@bb0155]). Because the polymorphisms at the promoter region and exon 1 were in complete linkage disequilibrium in all 7 patients ([Table 2](#t0010){ref-type="table"}), the haplotype was named *TYK2* promoter variant.

3.2. Significance of *TYK2* Promoter Variant {#s0050}
--------------------------------------------

We first studied the association of the missense change at exon 8 with diabetes. We compared 244 patients with T1D, 255 patients with T2D and 254 healthy controls, and found no measurable difference in the genotype frequency between diabetic patients and healthy controls (Supplementary Table 2).

We further compared the prevalence of *TYK2* promoter variant; GT/AA and AA combined, and compared with wild type GT in 302 patients with T1D, 314 patients with T2D and 331 healthy controls ([Table 1](#t0005){ref-type="table"}). Among them, 73 T1D patients had a flu-like syndrome at diabetes onset. The frequency of the *TYK2* promoter variant was significantly higher in patients with T1D (odds ratio (OR), 2.4; 95% confidence interval (CI), 1.2 to 4.6; *P* = 0.01), and also in patients with T2D (OR, 2.1; 95% CI, 1.1 to 4.1; *P* = 0.03), compared with healthy controls ([Table 3](#t0015){ref-type="table"}). Thus, the *TYK2* promoter variant was more frequent in all patients with diabetes compared with healthy controls (OR, 2.3; 95% CI, 1.2 to 4.1; *P* = 0.009) ([Table 3](#t0015){ref-type="table"}). The *TYK2* promoter variant was associated with a more evident increase in risk of T1D patients associated with a flu-like syndrome (OR, 3.6; 95% CI, 1.5 to 8.5; *P* = 0.005) ([Table 3](#t0015){ref-type="table"}). In addition, the *TYK2* promoter variant was significantly more frequent among T1D patients without anti-glutamic acid decarboxylase autoantibody (GAD) (OR, 3.3; 95% CI, 1.6 to 7.2; *P* = 0.002), but not among anti-GAD autoantibody-positive patients (OR, 1.7; 95% CI, 0.8 to 3.9; *P* = 0.21) ([Table 3](#t0015){ref-type="table"}).

It is thus suggested that the risk for diabetes conferred by the *TYK2* promoter variant is distinct from autoimmunity against pancreatic β-cells. We grouped TID associated with flu-like syndrome and analyzed the age at onset and anti-GAD antibody positivity, in association with *TYK2* promoter variant. There was no statistical significance in the age at onset (*P* = 0.16), but has significantly increased frequency in anti-GAD antibody negative T1D (OR, 5.0; 95% CI, 1.9 to 13.2; *P* = 0.0005) (Supplementary Table 3), consistent with the observation of all T1D patients. There was no gender difference in the frequency of *TYK2* promoter variant, among patients with T1D (male, 13/113; 11.5%, female, 16/189; 8.5%; *P* = 0.39), and also T2D (male, 14/161; 8.7%, female, 13/153; 8.5%; *P* = 0.95). In the age-specific analysis on subjects with T1D, we found that the *TYK2* promoter variant haplotype was associated with a higher risk for diabetes in younger people aged 0 to 19 years (OR, 2.4; 95% CI, 1.1 to 5.4; *P* = 0.04) and 20 to 39 years (OR, 3.1; 95% CI, 1.4 to 6.9; *P* = 0.006), but not in older patients aged 40--59 years (OR, 1.6; 95% CI, 0.5 to 5.1; *P* = 0.62) or 60--79 years (OR, 1.2; 95% CI, 0.1 to 9.5; *P* = 0.68) ([Table 4](#t0020){ref-type="table"}).

Thus, the *TYK2* promoter variant is associated with an increased risk of T1D with a younger age of onset.

In the age group of 20--39, we found no difference in the age at onset (*P* = 0.17), however, those with variant type are more associated with anti-GAD negative people (OR, 5.1; 95% CI, 1.9 to 13.6; *P* = 0.0003), and also with flu-like syndrome at the onset (OR, 4.8; 95% CI, 1.4 to 15.49; *P* = 0.022) (Supplementary Table 3), consistent with the observation in all T1D. Since obesity is an important risk for endocrinological disorders ([@bb0020]), we also analyzed the association between BMI and *TYK2* promoter variant in T2D. There was no difference in BMI between T2D with *TYK2* promoter wild type gene and variant type (*P* = 0.12) (Supplementary Table 4). In addition, there was increased *TYK2* promoter variant rate at statistical significance only in non-obese T2D with less than 26 BMI (OR, 2.4; 95% CI, 1.2 to 4.8; *P* = 0.01), but not obese T2D with more than 26 BMI (OR, 0.8; 95% CI, 0.2 to 3.7; *P* = 1.0) (Supplementary Table 4), suggesting that obesity is not likely involved in the increased risk associated with *TYK2* promoter variant in T2D.

3.3. Promoter Activity of the *TYK2* Promoter Variant {#s0055}
-----------------------------------------------------

To determine the function of the *TYK2* promoter variant gene, we performed a luciferase assay, and found that the variant type promoter showed significantly reduced promoter activity (82.29 ± 0.03%; *P* \< 0.001) (Supplementary Fig. 2A). Similarly, there was a slight decrease in the interferon-induced expressions of *TYK2* gene (mean ± SD of the relative expression; 0.59 ± 0.21) in peripheral blood mononuclear cells derived from diabetic patients with *TYK2* promoter variant (n = 14), compared with those (0.71 ± 0.28) of patients with the wild type *TYK2* gene (n = 17), while there was a mild increase in the interferon-induced expressions of *JAK1* gene (mean ± SD of the relative expression; before stimulation; 0.74 ± 0.19 to 0.82 ± 0.17 after stimulation) in peripheral blood mononuclear cells derived from diabetic patients with *TYK2* promoter variant (n = 14), compared with those (before stimulation; 0.82 ± 0.21 to 0.84 ± 0.21 after stimulation) of patients with the wild type *TYK2* gene (n = 17) (Supplementary Fig. 2B). The expression levels of ISGs, including *PKR*, *OAS* and *MxA*, induced by interferon stimulation in patients with *TYK2* promoter variant were also lower than those of patients with wild type ISGs (Supplementary Fig. 2C), which did not reach statistical significance (all: *P* \> 0.05). These results suggest that the increased risk of developing diabetes conferred by the *TYK2* promoter variant may be due to reduced *TYK2* promoter activity accompanied by the decreased expression of the *TYK2* gene and ISGs, while increased expression level of *JAK1* gene on IFN stimulation in patients with TYK2 promoter variant may play a complementary role for the deteriorated *TYK2* gene expression to maintain ISGs responses. Further investigation is required to clarify the influence of *TYK2* promoter variant on cytokine responses in humans.

4. Discussion {#s0020}
=============

In the present study, based on our experimental evidence that the natural susceptibility gene to EMC virus-induced diabetes was *Tyk2* in mice ([@bb0050]), we could extend those observations to humans, with a *TYK2* promoter variant which is associated with an overall increased risk for diabetes in Japanese subjects, particularly in patients with T1D associated with flu-like syndrome at onset. In addition, a genome wide study had identified the T1D susceptibility-associated region as 19p13 ([@bb0075]), where the *TYK2* gene is located (19p13.2)([@bb0030]). All these observations taken together indicate that the *TYK2* gene might be regarded as a good candidate for the virus-induced diabetes susceptibility gene in humans. Surprisingly, the *TYK2* gene promoter region variant was more frequent not only in subjects with T1D but also those with T2D. If *TYK2* promoter variant is actually associated with increased susceptibility to virus-induced diabetes, these results suggest that viral infection may be one of the risk factors for developing T2D, which is consistent with the concept that the accumulation of environmental insults will lead to clinical diabetes ([@bb0160]). Since *TYK2* gene is also associated with other several cytokine signals including IL-6, IL-10, IL-12, and IL-23 ([@bb0120], [@bb0005], [@bb0095]), suggesting that deteriorated cytokine responses that can modulate immune/inflammatory reactions, alone or in combination, due to *TYK2* promoter variant, may also play a role to serve an increased risk for diabetes. Accordingly, it has been indicated to have a close link between inborn errors or polymorphisms of *TYK2* gene and a wide spectrum of autoimmune diseases, inflammatory diseases, tumors, and obesity ([@bb0120], [@bb0005], [@bb0095], [@bb0015]). Therefore unknown factors associated with the *TYK2* promoter variant other than viral infection may also contribute to increase the risk for diabetes. At least, as indicated in our study, *TYK2* promoter variant in T2D was associated with non-obese patients but not with obesity.

Interestingly, *TYK2* promoter variant was associated with a significantly higher susceptibility to diabetes in anti-GAD antibody-negative patients (OR, 3.3; *P* = 0.002), of which observation is consistent with *Tyk2* gene mutation dependent murine virus-induced diabetes that simulates non-autoimmune rapid onset and fulminant T1D without autoantibody production ([@bb0045], [@bb0080], [@bb0050]). It was reported that the *Tyk2* gene played an important role not only in the interferon signaling pathway but also in the Th1 type immune response-associated IL-12-dependent signaling pathway ([@bb0105]). It was also reported that autoimmunity to pancreatic β-cells, associated with the development of T1D, was mainly dependent on Th1 type immune response ([@bb0035]). These observations suggest that the human *TYK2* gene promoter variant may reduce the risk for the development of Th1 type-dependent autoimmune reactivity to the pancreatic β-cells. In addition, if *TYK2* promoter variant confer risk for the development of diabetes due to increased susceptibility to viral-infection, possible induction of autoimmunity against pancreatic β-cells triggered by viral infections, which is a well-documented hypothesis ([@bb0025], [@bb0115]), was not a major pathogenic mechanism, in *TYK2* promoter variant-associated susceptibility to type 1 diabetes. Since these data have been obtained in the Japanese population, less prone to T1D than other ethnic groups, the possible role of *TYK2* promoter variant needs to be verified in different populations.

In human cases the situation is highly different from that in experimental animals where mice have been infected with a virus and it is possible to prove that infection is causing diabetes, however, accumulation of circumstantial evidence to identify the putative virus-induced susceptibility gene in humans is important. It was reported that polymorphisms of the *IFIH1* gene, which is an intracellular pathogen recognition receptor for picornavirus including enteroviruses, operating as an inducer of interferon production ([@bb0130]), is associated with risk or resistance for the T1D, serving possible virus-induced susceptibility gene in humans ([@bb0110], [@bb0085]). Since the outcome of virus-induced diabetes is influenced by many factors including viral diabetogenicity and host susceptibility, the discovery of other risk genes associated with virus-induced diabetes in addition to *IFIH1* and *TYK2* genes is both possible and feasible. Unfortunately, at present, there is no appropriate assay system to prove the diabetogenicity of the virus infective for humans, fulfilling 'Koch's postulate ([@bb0125]). Mouse models that are simulative of human virus-induced diabetes, with higher virus-induced diabetes susceptibility for use as an in vivo assay system to evaluate the diabetogenic potential of the possible viral agents that are infectious for humans. Mouse strains endowed with high susceptibility to picornavirus-induced diabetes may be used as in vivo models to evaluate the diabetogenicity of candidate human viruses.
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![Polymorphisms of *TYK2* gene 22 patients with type 1 diabetes associated with flu-like syndrome at the onset. Positions of mutations were described from transcription start point at exon 1.](gr1){#f0005}

###### 

Characteristics of patients with T1D and T2D, and healthy controls.

  Characteristics                                             Type 1 diabetes[a](#tf0005){ref-type="table-fn"}   Type 2 diabetes                       Healthy controls
  ----------------------------------------------------------- -------------------------------------------------- ------------------------------------- ----------------------
  Number                                                      302                                                314                                   331
  Age (years) (range)                                         40.7 ± 17.3 (7--83)                                61.8 ± 11.8 (17--91)                  43.4 ± 12.7 (18--71)
  Men (%)                                                     37.4                                               51.3                                  53.5
  HbA1c (%)[b](#tf0010){ref-type="table-fn"}                  8.9 ± 2.3                                          7.9 ± 1.6                             5.2 ± 0.7
  BMI (kg/m^2^)                                               21.8 ± 3.1                                         23.2 ± 3.6                            22.0 ± 3.3
  Age at diabetes onset (range)                               27.8 ± 17.9 (0--73)                                NA[c](#tf0015){ref-type="table-fn"}   NA
  Anti-GAD Ab[d](#tf0020){ref-type="table-fn"} positive (%)   58.6                                               NT[e](#tf0025){ref-type="table-fn"}   NT

Values are means ± standard deviation.

T1D, type 1 diabetes; T2D, type 2 diabetes.

Patients with T1D were diagnosed as they have fasting serum c-peptide level below 0.5 ng/ml.

HbA1c (%) was expressed as National Glycohemoglobin Standardization Program (NGSP) value.

NA: not available.

Anti-GAD ab: anti-glutamic acid decarboxylase antibody (≥ 1.5 U/ml).

NT: not tested.

###### 

Screening of *TYK2* gene polymorphism in 22 patients with T1D associated with flu-like syndrome at diabetes onset.

  Case no.   Age at the onset   Sex   SNPs at promoter region   SNPs at exon 1   SNP at exon 8                              
  ---------- ------------------ ----- ------------------------- ---------------- --------------- -------- -------- -------- --------
  1          49                 M                                                                                           
  2          47                 F     Hetero                    Hetero           Hetero          Hetero   Hetero   Hetero   
  3          61                 F     Hetero                    Hetero           Hetero          Hetero   Hetero   Hetero   
  4          31                 F                                                                                           
  5          36                 F                                                                                           Hetero
  6          40                 F                                                                                           Hetero
  7          59                 F                                                                                           Hetero
  8          9                  M     Homo                      Homo             Homo            Homo     Homo     Homo     
  9          10                 M                                                                                           
  10         43                 M     Hetero                    Hetero           Hetero          Hetero   Hetero   Hetero   
  11         52                 M     Hetero                    Hetero           Hetero          Hetero   Hetero   Hetero   Hetero
  12         53                 M                                                                                           Hetero
  13         34                 F     Hetero                    Hetero           Hetero          Hetero   Hetero   Hetero   
  14         24                 F                                                                                           Hetero
  15         62                 F                                                                                           Hetero
  16         35                 M     Hetero                    Hetero           Hetero          Hetero   Hetero   Hetero   Hetero
  17         25                 M                                                                                           
  18         30                 M                                                                                           
  19         48                 F                                                                                           
  20         40                 F                                                                                           
  21         24                 M                                                                                           Hetero
  22         27                 M                                                                                           Homo

T1D, type 1 diabetes.

Hetero: heterozygous polymorphism.

Homo: homozygous polymorphism.

###### 

*TYK2* promoter variant in patients with T1D and T2D, and healthy controls.

![](t1)

T1D, type 1 diabetes; T2D, type 2 diabetes.

^a^ Symptoms of flu-like syndrome include fever, chills, sore throat, muscle and joint aches, poor appetite, diarrhea, cough, and fatigue, suggestive of certain viral infections.

^b^ Referent.

^c^ OR, odds ratio.

^d^ CI, confidence interval.

^e^ Heterozygous (GT/AA) and homozygous (AA) variant genotypes combined (*TYK2* promoter variant) versus homozygous wild genotype (GT) between the cases and healthy controls was statistically assessed by χ^2^ test.

###### 

*TYK2* promoter variant genotypes in patients with T1D, with stratification by the age of onset.

  Age at onset   T1D (n = 302)   OR[a](#tf0055){ref-type="table-fn"} (95% CI[b](#tf0060){ref-type="table-fn"})   *P*-value[c](#tf0065){ref-type="table-fn"}                    
  -------------- --------------- ------------------------------------------------------------------------------- -------------------------------------------- ---------------- -------
  0--19          104 (90.4%)     10 (8.7%)                                                                       1 (0.9%)                                     2.4 (1.1--5.4)   0.04
  20--39         94 (87.9%)      13 (12.1%)                                                                      0 (0%)                                       3.1 (1.4--6.9)   0.006
  40--59         56 (93.3%)      4 (6.7%)                                                                        0 (0%)                                       1.6 (0.5--5.1)   0.62
  60--79         19 (95.0%)      1 (5.0%)                                                                        0 (0%)                                       1.2 (0.1--9.5)   0.68

T1D, type 1 diabetes.

OR, odds ratio.

CI, confidence interval.

Heterozygous and homozygous variant genotypes combined (*TYK2* promoter variant) versus homozygous wild genotype in comparison with healthy controls (see [Table 3](#t0015){ref-type="table"}).

[^1]: These authors contributed equally to this work.
